FDA grants fast track designation to PDS0101 for head and neck cancer subset

The FDA granted fast track designation to PDS0101 for treatment of certain patients with head and neck cancer.
The designation applies to use of the agent in combination with pembrolizumab (Keytruda, Merck) by patients with recurrent or metastatic HPV16-positive disease.
PDS0101 (PDS Biotechnology Corporation) is a T-cell HPV-specific immunotherapy delivered subcutaneously.
Prior studies have demonstrated its potential to stimulate high levels of HPV16-specific CD8-positive and CD4-positive T cells by activating multiple immune pathways, according to a PDS Biotech-issued press release. These T

The FDA granted fast track designation to PDS0101 for treatment of certain patients with head and neck cancer.
The designation applies to use of the agent in combination with pembrolizumab (Keytruda, Merck) by patients with recurrent or metastatic HPV16-positive disease.
PDS0101 (PDS Biotechnology Corporation) is a T-cell HPV-specific immunotherapy delivered subcutaneously.
Prior studies have demonstrated its potential to stimulate high levels of HPV16-specific CD8-positive and CD4-positive T cells by activating multiple immune pathways, according to a PDS Biotech-issued press release. These T